Atezolizumab was the first PD-L1 inhibitor confirmed active in bladder cancer and is currently the only PD-L1 inhibitor approved by the FDA for patients with metastatic or locally advanced urothelial carcinoma based on promising overall response rates in clinical trials (Bellmunt et al., 2017). Here, CD274 is linked to urinary bladder cancer.